SAR-3419: Antibody-drug immunoconjugate oncolytic

Drugs of the Future

Volumn 37, Issue 6, 2012, Pages 419-422

  Tuszynski, J A ^a,b  

^a CROSS CANCER INSTITUTE   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Acute lymphoblastic leukemia; HuB4 DM4; Monoclonal antibody; Non Hodgkin's lymphoma; SAR 3419

Indexed keywords

CD19 ANTIBODY; CYCLOPHOSPHAMIDE; DOXORUBICIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HUB4; PREDNISONE; RITUXIMAB; SAR 3419; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; BLURRED VISION; CANCER COMBINATION CHEMOTHERAPY; CORNEA DISEASE; DRUG CONJUGATION; DRUG DOSE ESCALATION; DRUG SAFETY; HUMAN; NONHODGKIN LYMPHOMA; NONHUMAN; REVIEW; TREATMENT RESPONSE;

EID: 84952981119     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2012.037.06.1825617     Document Type: Review

References (15)

1. Lutz, R.J., Zuany-Amorim, C., Vrignaud, P. et al. Preclinical evaluation of SAR3419 (huB4-DM4), an anti-CD19-maytansinoid immunoconjugate, for the treatment of B cell lymphomas. Proc Amer Assoc Cancer Res 2006, 47: Abst 3731.
2. Aboukameel, A., Goustin, A.S., Mohammad, R. Superior anti-tumor activity of the CD19-directed immunotoxin, SAR3419 to rituximab in non- Hodgkins xenograft animal models: Pre-clinical evaluation . Blood [49th Am Soc Hematol Annu Meet Exp (Dec 8-11, Atlanta) 2007] 2007, 110(11): Abst 2339.
3. Lock, R., Carol, H., Houghton, P. et al. Pediatric Pre-clinical Testing Program (PPTP) evaluation of the anti-CD19-DM4 conjugated antibody SAR3419. 20th AACR-NCI-EORTC Int Conf Mol Targets Cancer Ther (Oct 20-24, Brussels) 2008, Abst 192.
4. Erickson, H., Provenzano, C., Mayo, M. et al. Target-cell processing of the anti-CD19 antibody maytansinoid conjugate SAR3419 in pre-clinical models. 100th AACR Annu Meet (April 18-22, Denver) 2009, Abst 5473.
5. Al-Katib, A.M., Aboukameel, A., Mohammad, R., Bissery, M.C., Zuany- Amorim, C. Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma. Clin Cancer Res 2009, 15(12): 4038-45.
6. Blanc, V., Bousseau, A., Caron, A., Carrez, C., Lutz, R.J., Lambert, J.M. SAR3419: An anti-CD19-maytansinoid immunoconjugate for the treatment of B-cell malignancies. Clin Cancer Res 2011, 17(20): 6448-58.
7. Younes, A., Gordon, L., Kim, S. et al. Phase I multi-dose escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous (iv) infusion every 3 weeks to patients with relapsed/refractory B-cell non-Hodgkin's lymphoma (NHL). 51st Am Soc Hematol Annu Meet Exp (Dec 5-8, New Orleans) 2009, Abst 585.
8. Ricart, A.D. Immunoconjugates against solid tumors: Mind the gap. Clin Pharmacol Ther 2011, 89(4): 513-23.
9. SAR3419 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) (NCT00539682). ClinicalTrials.gov Web site, June 4, 2012.
10. Multi-dose-escalation safety and pharmacokinetic study of SAR3419 as single agent in relapsed/refractory B-cell non Hodgkin's lymphoma (NCT00549185). ClinicalTrials.gov Web site, June 4, 2012.
11. SAR3419 administered weekly in patients with relapsed/refractory CD19-positive B-cell Non-Hodgkin's lymphoma (NCT00796731). ClinicalTrials.gov Web site, June 4, 2012.
12. Coiffier, B., Ribrag, V., Dupuis, J. et al. Phase I/II study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered weekly to patients (pts) with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL). 47th Annu Meet Am Soc Clin Oncol (ASCO) (June 3-7, Chicago) 2011, Abst 8017.
13. SAR3419 in acute lymphoblastic leukemia (NCT01440179). ClinicalTrials.gov Web site, June 4, 2012.
14. SAR3419 as single agent in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) patients (STARLYTE) (NCT01472887). ClinicalTrials.gov Web site, June 4, 2012
15. Combination of SAR3419 and rituximab in relapsed/refractory diffuse large B-cell lymphoma (NCT01470456). ClinicalTrials.gov Web site, June 4, 2012.